Pulmonary Embolism And Anticoagulation Follow-Up
Help Questions
USMLE Step 3 › Pulmonary Embolism And Anticoagulation Follow-Up
A 44-year-old postpartum woman (3 weeks after delivery) was treated for PE diagnosed 10 days ago. Risk factors include recent pregnancy, prolonged bed rest, and obesity; no prior VTE. She is on warfarin with target INR 2.0–3.0 and is breastfeeding; INR checks occur every 3 days. She now reports mild hemoptysis and heavy vaginal bleeding soaking pads hourly. Vitals: BP 98/60, HR 112, SpO2 97% RA. Labs: INR 3.9, Hgb 7.9 g/dL, platelets 250k, creatinine 0.7 mg/dL. What is the most appropriate next step in management for this patient?
Switch to clopidogrel and schedule outpatient gynecology follow-up next month
Continue warfarin and reassure because uterine bleeding is common postpartum
Administer thrombolysis to prevent recurrent PE given hypotension and tachycardia
Hold warfarin, give reversal as needed, and urgently evaluate postpartum hemorrhage
Explanation
This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's INR of 3.9, heavy vaginal bleeding, hemoglobin drop, hypotension, and tachycardia are critical for decision-making. The correct answer addresses these factors by suggesting holding warfarin, giving reversal as needed, and urgently evaluating postpartum hemorrhage, demonstrating the application of clinical guidelines for major bleeding in the postpartum period. A common distractor might suggest continuing warfarin and reassuring the patient, which fails to consider the severity of bleeding and hemodynamic instability. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
A 72-year-old man on warfarin for PE 4 months ago (unprovoked) presents with sudden headache and confusion. He reports no chest pain or dyspnea. Risk factors include age and prior DVT; no malignancy. Regimen: warfarin with target INR 2.0–3.0; last INR 3.1 one week ago. Today vitals: BP 168/92, HR 88. Labs: INR 4.9, platelets 200k, creatinine 1.2 mg/dL (eGFR 66 mL/min/1.73 m²). What complication is this patient at greatest risk for given their current therapy?
Recurrent PE because INR above goal indicates insufficient anticoagulant effect
Heparin-induced thrombocytopenia from chronic warfarin exposure without heparin use
Acute renal failure caused directly by warfarin at therapeutic dosing
Intracranial hemorrhage due to supratherapeutic anticoagulation and neurologic symptoms
Explanation
This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's sudden headache, confusion, elevated INR of 4.9, and hypertension are critical for decision-making. The correct answer addresses these factors by identifying intracranial hemorrhage as the greatest risk due to supratherapeutic anticoagulation, demonstrating the application of clinical guidelines for recognizing serious bleeding complications. A common distractor might suggest recurrent PE, which fails to consider that elevated INR increases bleeding rather than thrombotic risk. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
A 61-year-old man is discharged 3 days ago after PE provoked by trauma and immobilization. He is on warfarin with enoxaparin bridge; target INR 2.0–3.0. He returns with mild hemoptysis and extensive ecchymoses on arms. Vitals stable. Labs: INR 4.2, Hgb 13.0 g/dL, platelets 220k, creatinine 1.6 mg/dL (eGFR 44 mL/min/1.73 m²). He has continued enoxaparin injections because he misunderstood instructions. Based on the scenario, what adjustment, if any, should be made to the patient's anticoagulation therapy?
Switch to dabigatran without considering renal function or bleeding symptoms
Increase enoxaparin dose and continue warfarin to treat suspected recurrent PE
Stop enoxaparin immediately and hold warfarin temporarily with prompt INR recheck
Continue both agents because dual therapy prevents early recurrent embolism
Explanation
This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's INR of 4.2, mild hemoptysis, ecchymoses, and continued enoxaparin bridge are critical for decision-making. The correct answer addresses these factors by suggesting stopping enoxaparin immediately and holding warfarin temporarily with INR recheck, demonstrating the application of clinical guidelines for managing overanticoagulation from prolonged bridging. A common distractor might suggest continuing both agents, which fails to consider the bleeding risk from dual therapy. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
A 47-year-old man on long-term anticoagulation for PE 3 months ago (provoked by long-haul flight and obesity) presents with new pleuritic chest pain and dyspnea on exertion. He is taking apixaban 5 mg twice daily; he admits missing several evening doses over the last week. No hemoptysis. Vitals: BP 132/80, HR 108, RR 22, SpO2 93% RA. Exam shows mild right calf tenderness. Labs: INR 1.1, creatinine 0.9 mg/dL (eGFR 95 mL/min/1.73 m²), troponin negative. He has no contraindications to contrast. What is the most appropriate next step in management for this patient?
Stop apixaban and start warfarin without parenteral bridging therapy
Obtain CT pulmonary angiography to evaluate for recurrent pulmonary embolism
Start NSAIDs for pleurisy and defer imaging until symptoms persist one week
Reassure and schedule routine follow-up because he is already anticoagulated
Explanation
This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's missed apixaban doses, new pleuritic chest pain, dyspnea, tachycardia, and hypoxia are critical for decision-making. The correct answer addresses these factors by suggesting CT pulmonary angiography to evaluate for recurrent pulmonary embolism, demonstrating the application of clinical guidelines for suspected recurrence in nonadherent patients. A common distractor might suggest reassurance without imaging, which fails to consider the risk of recurrence due to missed doses. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
A 55-year-old woman with recurrent unprovoked PE (two episodes, last 14 months ago) presents for routine anticoagulation follow-up. Risk factors include prior estrogen-containing OCP use (stopped), obesity, and strong family history of VTE; she has no active cancer. She is on warfarin with target INR 2.0–3.0, monitored every 4 weeks; last two INRs were 2.4 and 2.6. She now reports 3 days of dark stools, lightheadedness on standing, and increased bruising; no chest pain or dyspnea. Vitals: BP 104/66, HR 102, SpO2 98% RA. Exam shows conjunctival pallor and ecchymoses. Labs today: INR 3.8, Hgb 8.7 g/dL (baseline 12.1), platelets 210k, BUN 34 mg/dL, creatinine 1.3 mg/dL (eGFR 52 mL/min/1.73 m²). She recently started ibuprofen for back pain. What is the most appropriate next step in management for this patient?
Continue warfarin and add a proton pump inhibitor without further evaluation
Hold warfarin, administer reversal, and evaluate for gastrointestinal bleeding source urgently
Increase warfarin dose to maintain INR 3.5–4.5 for recurrent PE prevention
Switch to aspirin monotherapy and schedule outpatient colonoscopy in three months
Explanation
This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's INR of 3.8, dark stools, lightheadedness, hemoglobin drop, and recent ibuprofen use are critical for decision-making. The correct answer addresses these factors by suggesting holding warfarin, administering reversal, and urgently evaluating for gastrointestinal bleeding, demonstrating the application of clinical guidelines for major bleeding events. A common distractor might suggest continuing warfarin and adding a proton pump inhibitor, which fails to consider the urgency of reversal and evaluation in active bleeding. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
A 64-year-old man is seen 5 days after discharge for PE provoked by abdominal surgery. He is on warfarin with target INR 2.0–3.0; INR is checked every 2 days. He reports mild hemoptysis and new painful swelling in his left calf. Vitals: HR 105, SpO2 95% RA. Labs: INR 1.6, Hgb 13.9 g/dL, platelets 250k, creatinine 1.0 mg/dL (eGFR 80 mL/min/1.73 m²). What is the most appropriate next step in management for this patient?
Continue current warfarin dose and recheck INR at routine monthly interval
Give vitamin K to reverse warfarin because hemoptysis indicates overanticoagulation
Start therapeutic parenteral anticoagulation and obtain imaging for suspected recurrent DVT/PE
Stop anticoagulation and place IVC filter as first-line therapy for calf swelling
Explanation
This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's subtherapeutic INR of 1.6, mild hemoptysis, new painful calf swelling, tachycardia, and mild hypoxia are critical for decision-making. The correct answer addresses these factors by suggesting starting therapeutic parenteral anticoagulation and obtaining imaging for suspected recurrent DVT/PE, demonstrating the application of clinical guidelines for subtherapeutic anticoagulation with symptoms. A common distractor might suggest continuing the current warfarin dose, which fails to consider the risk of recurrence in subtherapeutic state. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
A 69-year-old man on warfarin for recurrent PE presents with new chest pain and dyspnea. He has been adherent; target INR 2.0–3.0. Risk factors include prior unprovoked VTE and obesity. Vitals: HR 118, BP 110/70, SpO2 90% RA. Labs: INR 2.6, creatinine 1.0 mg/dL (eGFR 76 mL/min/1.73 m²), Hgb 13.7 g/dL. He has no bleeding symptoms. What is the most appropriate next step in management for this patient?
Hold warfarin because dyspnea indicates anticoagulant toxicity and pulmonary hemorrhage
Discharge without workup because therapeutic INR excludes recurrent thromboembolism
Start prednisone for pleuritis and schedule outpatient follow-up in two weeks
Evaluate urgently for recurrent PE or alternative diagnosis despite therapeutic INR
Explanation
This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's therapeutic INR of 2.6, new chest pain, dyspnea, tachycardia, and hypoxia are critical for decision-making. The correct answer addresses these factors by suggesting urgent evaluation for recurrent PE or alternative diagnosis, demonstrating the application of clinical guidelines for symptoms despite therapeutic anticoagulation. A common distractor might suggest discharging without workup, which fails to consider that recurrence or other issues can occur even with therapeutic INR. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
A 58-year-old woman is seen 6 days after discharge for PE provoked by prolonged travel. She has obesity and varicose veins; no prior VTE. She is taking warfarin 5 mg nightly; target INR 2.0–3.0 with INR checks twice weekly. She reports mild hemoptysis and new petechiae but no dyspnea. Vitals stable. Labs: INR 1.7, Hgb 13.2 g/dL, platelets 18,000/µL, creatinine 0.9 mg/dL (eGFR 88 mL/min/1.73 m²). She received unfractionated heparin infusion during hospitalization. Which laboratory finding is most concerning given the patient's current condition?
Creatinine of 0.9 mg/dL indicating normal renal function on anticoagulation
INR of 1.7 suggesting slightly subtherapeutic warfarin requiring dose increase
Platelets of 18,000/µL suggesting severe thrombocytopenia after recent heparin exposure
Hemoglobin of 13.2 g/dL indicating no clinically significant bleeding
Explanation
This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's severe thrombocytopenia with platelets of 18,000/µL, mild hemoptysis, petechiae, and recent heparin exposure are critical for decision-making. The correct answer addresses these factors by identifying the platelet count as most concerning for heparin-induced thrombocytopenia, demonstrating the application of clinical guidelines for post-heparin complications. A common distractor might suggest the subtherapeutic INR as most concerning, which fails to consider the urgency of severe thrombocytopenia. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
A 68-year-old woman on rivaroxaban for unprovoked PE (18 months ago) presents for routine follow-up. Risk factors include obesity and prior DVT; no malignancy. She reports progressive fatigue and exertional dyspnea but no chest pain. She denies overt bleeding. Vitals: HR 92, BP 122/74, SpO2 97% RA. Labs: Hgb 8.9 g/dL (baseline 12.9), MCV 72 fL, platelets 310k, creatinine 1.1 mg/dL (eGFR 60 mL/min/1.73 m²), INR 1.2. Stool guaiac is positive. What is the most appropriate next step in management for this patient?
Continue rivaroxaban and start oral iron without investigating potential bleeding source
Evaluate for occult gastrointestinal bleeding while reassessing anticoagulation risks and benefits
Increase rivaroxaban dose because microcytosis indicates recurrent pulmonary embolism
Stop anticoagulation immediately without evaluation because guaiac positivity is definitive
Explanation
This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's progressive fatigue, exertional dyspnea, anemia, microcytosis, and positive stool guaiac are critical for decision-making. The correct answer addresses these factors by suggesting evaluation for occult gastrointestinal bleeding while reassessing anticoagulation risks and benefits, demonstrating the application of clinical guidelines for managing chronic bleeding on DOACs. A common distractor might suggest continuing rivaroxaban without investigation, which fails to consider the need to identify and address the bleeding source. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.
A 52-year-old woman with recurrent PE on warfarin (target INR 2.0–3.0) presents with new unilateral leg swelling and mild dyspnea. She reports adherence but recently began a strict low-carbohydrate diet with increased leafy greens. Vitals: HR 104, SpO2 94% RA. Labs: INR 1.5, Hgb 13.8 g/dL, platelets 240k, creatinine 0.8 mg/dL (eGFR 96 mL/min/1.73 m²). What is the most appropriate next step in management for this patient?
Evaluate for recurrent VTE and initiate therapeutic anticoagulation while awaiting imaging
Reassure because low INR is expected with diet changes and no action is needed
Administer vitamin K to reverse warfarin and prevent bleeding complications
Stop warfarin and start aspirin because INR monitoring is unreliable
Explanation
This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's subtherapeutic INR of 1.5, new unilateral leg swelling, mild dyspnea, tachycardia, hypoxia, and recent diet changes are critical for decision-making. The correct answer addresses these factors by suggesting evaluation for recurrent VTE and initiating therapeutic anticoagulation while awaiting imaging, demonstrating the application of clinical guidelines for subtherapeutic anticoagulation. A common distractor might suggest reassurance due to diet changes, which fails to consider the clinical signs of possible recurrence. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.